Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404797 | 0.81 | METAP2 (0.49) | HTTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL26575330 | 0.80 | ALDH1A1 (0.55) | HTTLCKL3MBTL1ALDH1A1LMNA | |
| SCHEMBL2404746 | 0.78 | PDK1 (0.43) | CYP2C9CYP2C19CISD2CYP1A2 | |
| SCHEMBL108868 | 0.77 | ATR (0.51) | HTTLCKL3MBTL1ALDH1A1CISD2 | |
| SCHEMBL13548419 | 0.74 | CYP2C9 (0.46) | HTTCYP2C9CYP2C19NPSR1LCK | |
| SCHEMBL23885529 | 0.73 | HTT (0.47) | HTTLCKL3MBTL1ALDH1A1LMNA | |
| SCHEMBL15865840 | 0.73 | HTT (0.47) | HTTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL30254442 | 0.73 | HTT (0.47) | HTTLCKL3MBTL1ALDH1A1LMNA | |
| SCHEMBL525434 | 0.72 | CYP2C9 (0.43) | CYP2C9CYP2C19NPSR1L3MBTL1CISD2 | |
| SCHEMBL108498 | 0.72 | LCK (0.50) | HTTLCKL3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | disclosed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | HTT 2465/4885CYP2C9 383/4885CYP2C19 606/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | HTT 2465/4885CYP2C9 383/4885CYP2C19 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.